Tic suppression: The medical model

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 4, 2010, Pages 263-276

  Wu, Steve W ^a   Harris, Elana ^a   Gilbert, Donald L ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; BOTULINUM TOXIN; CANNABINOID; CLONIDINE; DONEPEZIL; ETIRACETAM; GUANFACINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PERGOLIDE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TIAPRIDE; TOPIRAMATE; ZIPRASIDONE;

AKATHISIA; ANXIETY; APPETITE; ASPIRATION; BINDING AFFINITY; BLURRED VISION; BRAIN DEPTH STIMULATION; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC SYSTEM; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG ANTAGONISM; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HOARSENESS; HUMAN; HYPOPHONIA; INSULIN RESISTANCE; METABOLIC DISORDER; MOTOR PERFORMANCE; MUSCLE CRAMP; OUTCOME ASSESSMENT; PAIN; PHOBIA; PTOSIS; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; SIDE EFFECT; SPEECH DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; WEAKNESS; WEIGHT GAIN;

CHILD; DEEP BRAIN STIMULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; PAIN; SEVERITY OF ILLNESS INDEX; TICS; TOURETTE SYNDROME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 77956408312     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2010.0015     Document Type: Review

References (144)

1. Abuzzahab FS, Brown VL: Control of Tourette's syndrome with to-piramate. Am J Psychiatry 158:968, 2001.
2. Ackermans L, Temel Y, Bauer NJ, Visser-Vandewalle V: Vertical gaze palsy after thalamic stimulation for Tourette syndrome: Case report. Neurosurgery 61:E1100; discussion E1100, 2007.
3. Ackermans L, Temel Y, Cath D, van der Linden C, Bruggeman R, Kleijer M, Nederveen P, Schruers K, Colle H, Tijssen MA, Visser-Vandewalle V: Deep brain stimulation in Tourette's syndrome: Two targets? Mov Disord 21:709-713, 2006. (Pubitemid 43792758)
4. Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, Pascual-Sedano B, Gironell A, Kulisevsky J: Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord 14:443-445, 2008.
5. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941-1949, 2005.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
7. Anca MH, Giladi N, Korczyn AD: Ropinirole in Gilles de la Tourette syndrome. Neurology 62:1626-1627, 2004.
8. Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Pelham WE, Richters JE, Schiller E, Severe JB, Swanson JM, Vereen D, Wells KC: National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Arch Gen Psychiatry 54:865-870, 1997.
9. Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 20:714-718, 2005.
10. Bajwa RJ, de Lotbiniere AJ, King RA, Jabbari B, Quatrano S, Kunze K, Scahill L, Leckman JF: Deep brain stimulation in Tourette's syndrome. Mov Disord 22:1346-1350, 2007.
11. Bastiampillai T, Dhillon R, Mohindra R: Exacerbation of tics secondary to clozapine therapy. Aust NZ J Psychiatry 42:1068-1070, 2008.
12. Bernard BA, Stebbins GT, Siegel S, Schultz TM, Hays C, Morrissey MJ, Leurgans S, Goetz CG: Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord 24: 1070-1073, 2009.
13. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73-e84, 2008.
14. Black KJ, Mink JW: Response to levodopa challenge in Tourette syndrome. Mov Disord 15:1194-1198, 2000.
15. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF: Meta-Analysis: Treatment of attention-deficit hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48:884-893, 2009.
16. Boon-yasidhi V, Kim YS, Scahill L: An open-label, prospective study of guanfacine in children with ADHD and tic disorders. J Med Assoc Thai 88 Suppl 8:S156-S162, 2005.
17. Brand N, Geenen R, Oudenhoven M, Lindenborn B, van der Ree A, Cohen-Kettenis P, Buitelaar JK: Brief report: Cognitive functioning in children with Tourette's syndrome with and without comorbid ADHD. J Pediatr Psychol 27:203-208, 2002.
18. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawk-ridge SM, Temlett JA: Risperidone versus pimozide in Tourette's disorder: A comparative double-blind parallel-group study. J Clin Psychiatry 62:50-56, 2001.
19. Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, Simon E: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 18:509-515, 2008.
20. Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 62:290-294, 2001.
21. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96, 1996.
22. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH: The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317-320, 1979.
23. Canitano R, Vivanti G: Tics and Tourette syndrome in autism spectrum disorders. Autism 11:19-28, 2007.
24. Chae JH, Nahas Z, Wassermann E, Li X, Sethuraman G, Gilbert D, Sallee FR, George MS: A pilot safety study of repetitive trans-cranial magnetic stimulation (rTMS) in Tourette's syndrome. Cogn Behav Neurol 17:109-117, 2004.
25. Chouinard S, Ford B: Adult onset tic disorders. J Neurol Neurosurg Psychiatry 68:738-743, 2000.
26. Correll CU, Kane JM: One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation anti-psychotics: A systematic review. J Child Adolesc Psychopharmacol 17:647-656, 2007.
27. Cubo E, Fernandez Jaen A, Moreno C, Anaya B, Gonzalez M, Kompoliti K: Donepezil use in children and adolescents with tics and attention-deficit/ hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 30: 182-189, 2008.
28. Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study. Clin Neuropharmacol 25:325-332, 2002.
29. Dehning S, Mehrkens JH, Muller N, Botzel K: Therapy-refractory Tourette syndrome: Beneficial outcome with globus pallidus in-ternus deep brain stimulation. Mov Disord 23:1300-1302, 2008.
30. Diederich NJ, Kalteis K, Stamenkovic M, Pieri V, Alesch F: Efficient internal pallidal stimulation in Gilles de la Tourette syndrome: A case report. Mov Disord 20:1496-1499, 2005.
31. Dooley JM, Gordon KE, Wood EP, Camfield CS, Camfield PR: The utility of the physical examination and investigations in the pedi-atric neurology consultation. Pediatr Neurol 28:96-99, 2003.
32. Dooley JM, Stokes A, Gordon KE: Pseudo-tics in Tourette syndrome. J Child Neurol 9:50-51, 1994.
33. Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB: Randomized double-blind mul-ticentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 42:807-813, 2008.
34. Earley CJ, Yaffee JB, Allen RP: Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 51:1599-1602, 1998.
35. Feinberg M, Carroll BJ: Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry 36:979-985, 1979.
36. Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B, Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 13:541-545, 2009.
37. Flaherty AW, Williams ZM, Amirnovin R, Kasper E, Rauch SL, Cosgrove GR, Eskandar EN: Deep brain stimulation of the anterior internal capsule for the treatment of Tourette syndrome: Technical case report. Neurosurgery 57:E403, 2005; discussion E403.
38. Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P: An international perspective on Tourette syndrome: Selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 42:436-447, 2000.
39. Gadow KD, DeVincent CJ, Schneider J: Comparative study of children with ADHD only, autism spectrum disorder + ADHD, and chronic multiple tic disorder + ADHD. J Atten Disord 12:474-485, 2009.
40. Gallagher CL, Garell PC, Montgomery EB Jr.: Hemi tics and deep brain stimulation. Neurology 66:E12, 2006.
41. Gilbert D: Treatment of children and adolescents with tics and Tourette syndrome. J Child Neurol 21:690-700, 2006.
42. Gilbert DL: Deep brain stimulation for a teen with tics? Neurology 68:85-85, 2007.
43. Gilbert DL, Buncher CR: Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette's syndrome: A model for studies of multiple neuropsychiatric diagnoses. J Neuropsychiatry Clin Neurosci 17:324-332, 2005.
44. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR: Tic reduction with pergolide in a randomized controlled trial in children. Neurology 60:606-611, 2003.
45. Goethals I, Jacobs F, Van der Linden C, Caemaert J, Audenaert K: Brain activation associated with deep brain stimulation causing dissociation in a patient with Tourette's syndrome. J Trauma Dissociation 9:543-549, 2008.
46. Goetz CG, Tanner CM, Wilson RS, Carroll VS, Como PG, Shannon KM: Clonidine and Gilles de la Tourette's syndrome: Double-blind study using objective rating methods. Ann Neurol 21:307-310, 1987.
47. Harris KM, Mahone EM, Singer HS: Nonautistic motor stereotypies: Clinical features and longitudinal follow-up. Pediatr Neurol 38:267-272, 2008.
48. Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 40:420-425, 2009.
49. Ho CS, Chen HJ, Chiu NC, Shen EY, Lue HC, Ho C-S, Chen H-J, Chiu N-C, Shen E-Y, Lue H-C: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 108:788-793, 2009.
50. Houeto JL, Karachi C, Mallet L, Pillon B, Yelnik J, Mesnage V, Welter ML, Navarro S, Pelissolo A, Damier P, Pidoux B, Dormont D, Cornu P, Agid Y: Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry 76:992-995, 2005.
51. Hounie AG, Pauls DL, Mercadante MT, Rosario-Campos MC, Shavitt RG, de Mathis MA, de Alvarenga PG, Curi M, Miguel EC: Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. J Clin Psychiatry 65:994-999, 2004.
52. Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on pro-lactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137-143, 1996.
53. Isaacs KM, Kao E, Johnson MD, Gilbert DL. Precipitating events and significant life stressors of pediatric patients diagnosed with a psychogenic movement disorder. Presented at the 37th Annual Meeting of the International Neuropsychological Society, Atlanta, GA, 2009.
54. Itard J: Meemoire sur quelques fonctions involontaires des appareils de la locomotion, de la prehension et de la voix. Arch Gen Med 8:385407, 1825.
55. Jankovic J: Botulinum toxin in the treatment of dystonic tics. Mov Disord 9:347-349, 1994.
56. Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81:70-73, 2010.
57. Jankovic J, Mejia NI: Tics associated with other disorders. Adv Neurol 99:61-68, 2006.
58. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140, 2002.
59. Karp B, Wassermann E, Porter S, Hallett M: Transcranial magnetic stimulation acutely decreases motor tics. Neurology 48:A397, 1997.
60. Kompoliti K, Goetz CG: Hyperkinetic movement disorders mis-diagnosed as tics in Gilles de la Tourette syndrome. Mov Disord 13:477-480, 1998.
61. Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, Kasper S: IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psycho-pharmacology (Berl) 133:323-328, 1997.
62. Kuhn J, Lenartz D, Mai JK, Huff W, Lee SH, Koulousakis A, Klos-terkoetter J, Sturm V: Deep brain stimulation of the nucleus ac-cumbens and the internal capsule in therapeutically refractory Tourette syndrome. Neurol 254:963-965, 2007.
63. Kuo SH, Jimenez-Shahed J: Topiramate in treatment of tourette syndrome. Clin Neuropharmacol 33:32-34, 2010.
64. Kurlan R, Como PG, Miller B, Palumbo D, Deeley C, Andresen EM, Eapen S, McDermott MP: The behavioral spectrum of tic disorders: A community-based study. Neurology 59:414-420, 2002.
65. Kurlan R, Deeley C, Como PG: Psychogenic movement disorder (pseudo-tics) in a patient with Tourette's syndrome. J Neuropsychiatry Clin Neurosci 4:347-348, 1992.
66. Kurlan R, McDermott MP, Deeley C, Como PG, Brower C, Eapen S, Andresen EM, Miller B: Prevalence of tics in schoolchildren and association with placement in special education. Neurology 57:1383-1388, 2001.
67. Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 57:1190-1193, 2000.
68. Lang AE: Clinical phenomenology of tic disorders selected aspects. Adv Neurol 58:25-32, 1992.
69. Leckman JF: Tourette's syndrome. Lancet 360:1577-1586, 2002.
70. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ: The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573, 1989.
71. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, Kim YS, Peterson BS: Course of tic severity in Tourette syndrome: The first two decades. Pediatrics 102:14-19, 1998.
72. Lipinski JF, Sallee FR, Jackson C, Sethuraman G: Dopamine agonist treatment of Tourette disorder in children: Results of an open-label trial of pergolide. Mov Disord 12:402-407, 1997.
73. Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ: Aripiprazole in children and adolescents with Tourette's disorder: An open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19:623-633, 2009.
74. Maciunas RJ, Maddux BN, Riley DE, Whitney CM, Schoenberg MR, Ogrocki PJ, Albert JM, Gould DJ: Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg 107:1004-1014, 2007.
75. Mantovani A, Leckman JF, Grantz H, King RA, Sporn AL, Lisanby SH: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: Report of two cases. Clin Neurophysiol 118:2314-2315, 2007.
76. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 9:95-100, 2006.
77. March JS, Franklin ME, Leonard H, Garcia A, Moore P, Freeman J, Foa E: Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 61:344-347, 2007.
78. Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial. Neurology 56:605-610, 2001.
79. Martinez-Torres I, Hariz MI, Zrinzo L, Foltynie T, Limousin P: Improvement of tics after subthalamic nucleus deep brain stimulation. Neurology 72:1787-1789, 2009.
80. McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psycho-pharmacol 18:501-508, 2008.
81. Meige H, Feindel ECL: Tics and Their Treatment, edited by SAK. Wilson. London: S. Appleton, 1907, pp 298-314.
82. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 Suppl B:47-52, 1994.
83. Mercadante MT, Campos MC, Marques-Dias MJ, Miguel EC, Leck-man J: Vocal tics in Sydenham's chorea. J Am Acad Child Adolesc Psychiatry 36:305-306, 1997.
84. Mink JW: Clinical review of DBS for tourette syndrome. Front Biosci (Elite Ed) 1:72-76, 2009.
85. Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser-Vandewalle V, Vitek JL: Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord 21:1831-1838, 2006.
86. Mrakic-Sposta S, Marceglia S, Mameli F, Dilena R, Tadini L, Priori A: Transcranial direct current stimulation in two patients with Tourette syndrome. Mov Disord 23:2259-2261, 2008.
87. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 13:295-299, 2003.
88. Muller-Vahl KR: [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt 78:264, 266268, 270-261, 2007.
89. Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM, Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry 64:459-465, 2003.
90. Munchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM: Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology 59:1789-1791, 2002.
91. Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M, Yang M: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 19:441-447, 2009.
92. Nardocci N, Rumi V, Combi ML, Angelini L, Mirabile D, Bruzzone MG: Complex tics, stereotypies, and compulsive behavior as clinical presentation of a juvenile progressive dystonia suggestive of Hallervorden-Spatz disease. Mov Disord 9:369-371, 1994.
93. Nestadt G, Addington A, Samuels J, Liang KY, Bienvenu OJ, Riddle M, Grados M, Hoehn-Saric R, Cullen B: The identification of OCD-related subgroups based on comorbidity. Biol Psychiatry 53:914-920, 2003.
94. Nestadt G, Di CZ, Riddle MA, Grados MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Rasmussen SA, Cullen B, Pinto A, Knowles JA, Piacentini J, Pauls DL, Bienvenu OJ, Wang Y, Liang KY, Samuels JF, Roche KB: Obsessive-compulsive disorder: Subclassification based on co-morbidity. Psychol Med 39:1491-1501, 2009.
95. Newman-Tancredi A, Verriele L, Touzard M, Millan MJ: Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: Relationship to efficacy for G-protein activation. Eur J Pharmacol 428:177-184, 2001.
96. Nicolson R, Craven-Thuss B, Smith J, McKinlay BD, Castellanos FX, Nicolson R, Craven-Thuss B, Smith J, McKinlay BD, Castellanos FX: A randomized, double-blind, placebo-controlled trial of me-toclopramide for the treatment of Tourette's disorder. J Am Acad Child Adolesc Psychiatry 44:640-646, 2005.
97. Orth M, Kirby R, Richardson MP, Snijders AH, Rothwell JC, Trimble MR, Robertson MM, Munchau A: Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with Gilles de la Tourette syndrome. Clin Neurophysiol 116:764-768, 2005.
98. Peterson BS, Leckman JF: The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry 44:1337-1348, 1998.
99. Peterson BS, Pine DS, Cohen P, Brook JS: Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/hyperactivity disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry 40:685-695, 2001.
100. Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 24:420-423, 2004.
101. Porta M, Sassi M, Ali F, Cavanna AE, Servello D: Neurosurgical treatment for Gilles de la Tourette syndrome: The Italian perspective. J Psychosom Res 67:585-590, 2009.
102. Pringsheim T, Marras C: Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2:CD006996, 2009.
103. Rath JJ, Tavy DL, Wertenbroek AA, van Woerkom TC, de Bruijn SF: Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects. Parkinsonism Relat Disord 2009. [Epub ahead of print]
104. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:2939, 2000.
105. Ridding MC, Rothwell JC: Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev 8:559-567, 2007.
106. Robertson MM: Tourette syndrome, associated conditions and the complexities of treatment. Brain 123 Pt 3:425-462, 2000.
107. Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 13:229235, 1990.
108. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000.
109. Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, Brin MF: Botulinum toxin for refractory vocal tics. Mov Disord 11:746-748, 1996.
110. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:10671074, 2001.
111. Scahill L, Erenberg G, Berlin CM Jr., Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J: Contemporary assessment and pharmacother-apy of Tourette syndrome. NeuroRx 3:192-206, 2006.
112. Schneider SA, Robertson MM, Rizzo R, Turk J, Bhatia KP, Orth M: Fragile X syndrome associated with tic disorders. Mov Disord 23:1108-1112, 2008.
113. Scott BL, Jankovic J, Donovan DT: Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 11:431-433, 1996.
114. Searcy E, Burd L, Kerbeshian J, Stenehjem A, Franceschini LA: Asperger's syndrome, X-linked mental retardation (MRX23), and chronic vocal tic disorder. J Child Neurol 15:699-702, 2000.
115. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA: Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113,1995.
116. Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 18:197-205, 2008.
117. Servello D, Porta M, Sassi M, Brambilla A, Robertson MM: Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: The surgery and stimulation. J Neurol Neurosurg Psychiatry 79:136-142, 2008.
118. Servello D, Sassi M, Brambilla A, Porta M, Haq I, Foote KD, Okun MS: De novo and rescue DBS leads for refractory Tourette syndrome patients with severe comorbid OCD: A multiple case report. J Neurol 256:1533-1539, 2009.
119. Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J: GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology 68:159-160, 2007.
120. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsycho-pharmacology 28:1400-1411, 2003.
121. Shields DC, Cheng ML, Flaherty AW, Gale JT, Eskandar EN: Mi-croelectrode-guided deep brain stimulation for Tourette syndrome: Within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 86:87-91, 2008.
122. Singer HS, Mink JW, Gilbert DL, Jankovic J: Drug-Induced Movement Disorders in Children. Philadelphia, PA: Saunders, an imprint of Elsevier, 2010.
123. Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 22:1764-1770, 2007.
124. Snider LA, Seligman LD, Ketchen BR, Levitt SJ, Bates LR, Garvey MA, Swedo SE: Tics and problem behaviors in schoolchildren: Prevalence, characterization, and associations. Pediatrics 110:331336, 2002.
125. Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M: Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 11:470-481, 2008.
126. Stephens RJ, Bassel C, Sandor P: Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome-a pilot study. J Child Adolesc Psychopharmacol 14:255-266, 2004.
127. Sukhodolsky DG, Scahill L, Zhang H, Peterson BS, King RA, Lom-broso PJ, Katsovich L, Findley D, Leckman JF: Disruptive behavior in children with Tourette's syndrome: Association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry 42:98-105, 2003.
128. Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 19:3-14, 2004.
129. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073-1086, 1999.
130. The Pediatric OCD Treatment Study Team: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292:1969-1976, 2004.
131. Toren P, Weizman A, Ratner S, Cohen D, Laor N, Toren P, Weizman A, Ratner S, Cohen D, Laor N: Ondansetron treatment in Tourette's disorder: A 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 66:499-503, 2005.
132. Tourette Syndrome Study Group: Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 58:527-536, 2002.
133. Trimble MR, Whurr R, Brookes G, Robertson MM: Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 13:617-619, 1998.
134. Vincent DA Jr.: Botulinum toxin in the management of laryngeal tics. J Voice 22:251-256, 2008.
135. Visser-Vandewalle V, Ackermans L, van der Linden C, Temel Y, Tijssen MA, Schruers KR, Nederveen P, Kleijer M, Boon P, Weber W, Cath D: Deep brain stimulation in Gilles de la Tourette's syndrome. Neurosurgery 58:E590, 2006.
136. Visser-Vandewalle V, Temel Y, Boon P, Vreeling F, Colle H, Hoogland G, Groenewegen HJ, van der Linden C: Chronic bilateral thalamic stimulation: A new therapeutic approach in intractable Tourette syndrome. Report of three cases. J Neurosurg 99:1094-1100, 2003.
137. Visser-Vandewalle V, van der Linden C, Groenewegen HJ, Caemaert J: Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 353:724, 1999.
138. Welter ML, Mallet L, Houeto JL, Karachi C, Czernecki V, Cornu P, Navarro S, Pidoux B, Dormont D, Bardinet E, Yelnik J, Damier P, Agid Y: Internal pallidal and thalamic stimulation in patients with Tourette syndrome. Arch Neurol 65:952-957, 2008.
139. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J: Topiramate for migraine prevention in children: A randomized, double-blind, placebo-controlled trial. Headache 45:1304-1312, 2005.
140. Wonodi I, Reeves G, Carmichael D, Verovsky I, Avila MT, Elliott A, Hong LE, Adami HM, Thaker GK: Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord 22:1777-1782, 2007.
141. Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topcu M, Vanier MT, Widner H, Wijburg FA, Patterson MC: Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98:152-165, 2009.
142. Yamamoto T, Hirose G, Shimazaki K, Takado S, Kosoegawa H, Saeki M: Movement disorders of familial neuroacanthocytosis syndrome. Arch Neurol 39:298-301, 1982.
143. Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK, Brewer CC, Solomon B, Pavan WJ, Arcos-Burgos M, Patterson MC, Porter FD: Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neu-ropsychiatr Genet 153B:132-140, 2010.
144. Zabek M, Sobstyl M, Koziara H, Dzierzecki S: Deep brain stimulation of the right nucleus accumbens in a patient with Tourette syndrome. Case report. Neurol Neurochir Pol 42:554-559, 2008.